Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Prescription costs wikipedia , lookup
Plateau principle wikipedia , lookup
Clinical trial wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Drug discovery wikipedia , lookup
Electronic prescribing wikipedia , lookup
Intravenous therapy wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
NH3 [13N]ammonia Radiopharmaceutical Name 13 Radiopharmaceutical Image Normal 13NH3 Stress / Rest NH3, 13N-ammonia , [13N]NH3 Abbreviations: NH3, N-13 ammonia Normal Biodistribution Radiopharmaceutical Structure The circulation mean transit time of 13N ammonia from the circulation is 1.08 minutes, 0.064 of the administered activity returns to the circulation as metabolites with a half-time of approximately 2 minutes. Approximately, 7.1% and 6.9% are taken up in liver and brain, respectively. Approximately 6.4% enters the urinary bladder with a half-time of 8 minutes. (ICRP Publication 53,1994) image courtesy of James. H Caldwell, MD University of Washington Radionuclide 13 N Half-life 9.965 minutes Emission Emission positron: Emax 0.492 MeV MICAD http://www.ncbi.nlm.nih.gov/pubmed/books/NBK23075/ pdf/AmmoniaN13.pdf Developed by the SNMMI PET Center of Excellence and the Center for Molecular Imaging Innovation & Translation December 2012 - 1 NH3 [13N]ammonia Molecular Formula and Weight 13 General Tracer Class Clinical Diagnostic PET Radiopharmaceutical Target In vivo, 13NH3 is in the form of ammonium ion. After IV injection it is extracted from the capillaries through the ammonia transporter. Once in cells, it is converted to glutamine and can diffuse out of the cell or be metabolized to glutamate and retained within the cell. Targets all viable tissue that has blood flow but the clinical target is myocardial perfusion. (References: Khademi et al. 2004, Adeva et al. 2012, Feinstein Institute for Medical Research, Highlights of Prescribing Information for Ammonia 13N Injection for intravenous use 2011) Molecular Process Imaged Blood vessel perfusion of tissues in general proportional to blood flow. Mechanism for in vivo retention Enters cell via the ammonium transporter with accumulation in tissue in proportion to blood perfusion of the tissue. Retention is due to the ammonium conversion to glutamate or other metabolites (References: Khademi et al. 2004, Adeva et al. 2012, Feinstein Institute for Medical Research, Highlights of Prescribing Information for Ammonia 13N Injection for intravenous use 2011) Metabolism 13 N-ammonia undergoes a five-enzyme step metabolism in the liver to yield 13N-urea, the main circulating metabolite. It is also metabolized to 13N-glutamine, the main metabolite in tissues, by glutamine synthase in the skeletal muscles, liver, brain, myocardium, and other organs. Other metabolites of 13N-ammonia include small amounts of 13N-amino acid anions (acidic amino acids) in the forms of 13N-glutamate or 13N-aspartate. 13Nammonia is eliminated from the body by urinary excretion mainly as 13N-urea. (Feinstein Institute for Medical Research, Highlights of Prescribing Information for 13N-ammonia Injection for intravenous use 2011). With exercise, some ammonia may be released from skeletal muscle to the vessels (Adeva 2012) Radiosynthesis Most sites use a synthesis method reported by Berridge (1993) in which water containing a small amount of ethanol is irradiated with protons in a nuclear reaction followed by a radiation chemistry process to form the 13 NH4+ (ammonium ion) in the target. Additional information available at Molecular Imaging and Contrast Agent Database (MICAD), Bethesda (MD): National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/pubmed/books/NBK23075/ pdf/AmmoniaN13.pdf for [13N]ammonia, author Cheng. Availability The short half-life of 13N requires a nearby cyclotron. As for any PET radiopharmaceutical, an IND, NDA or NH3 16.02 g atom mole-1 Developed by the SNMMI PET Center of Excellence and the Center for Molecular Imaging Innovation & Translation December 2012 - 2 NH3 [13N]ammonia ANDA filed with the Food and Drug Administration (FDA) is required for human use.* Status with USP / EuPh The radiopharmaceutical is approved by the FDA, and is listed in USP and EuPh. Recommended Activity and Allowable mass DOSAGE AND ADMINISTRATION (taken from Prescribing Information) IV administration, typically 10-20 mCi (370 – 740 MBq) as a bolus (Feinstein Institute for Medical Research, Highlights of Prescribing Information for Ammonia 13N Injection for intravenous use 2011) Dosimetry The effective dose equivalent (whole body) is estimated to be 0.0027 mSv/MBq (10 mrem/mCi) for adults. The critical organs are the kidneys, which receive 0.0046 mGy/MBq (17 mrad/mCi) for adults (ICRP Publication No. 53 1994). Additional radiation absorbed dose information is provided in the ICRP publication and in the Feinstein Institute for Medical Research, Highlights of Prescribing Information for Ammonia 13N Injection for intravenous use.). Pharmacology and Toxicology Following intravenous injection, 13N-ammonia is cleared rapidly from the blood with a biologic half-life of about 2.84 minutes (effective half-life of about 2.2 minutes). In the myocardium, its biologic half-life has been estimated to be less than 2 minutes (effective half-life less than 1.67 minutes). In the brain its biologic half-life is less than 3 seconds. The mass of 13N-ammonia injected for imaging is very small compared to the normal range of ammonia in the blood (0.72 – 3.30 mg) in a 70 kg healthy adult man. Current Clinical Trials Reference Site / Person Imaging Protocol Reference: Feinstein Institute for Medical Research, Highlights of Prescribing Information for Ammonia 13N Injection for intravenous use. The NIH clinical trials registry (www.clinicaltrials.gov) should be consulted for a list of current trials using 13Nammonia. As of December 2012, three clinical trials were listed for the United States, only one that was still accruing patients. The best reference at this time for the state of 13NH3 trials is clinical trials.gov The imaging protocol for 13N-ammonia can vary. A typical example is: Rest Imaging Study : • Administer 10-20 mCi (370 – 740 MBq) as a bolus through a catheter inserted into a large peripheral vein. • Start imaging 3 minutes after the injection and acquire images for a total of 10-20 minutes. Stress Imaging Study: • If a rest imaging study is performed, begin the stress imaging study 40 minutes or more after the first 13Nammonia injection to allow sufficient isotope decay. • Administer a pharmacologic stress-inducing drug in accordance with its labeling. • Administer 10-20 mCi (370 – 740 MBq) of 13N-ammonia as a bolus at peak stress (exact time point may vary depending on stress agent, for instance at 7 min when dipyridamole as stress agent is given over 4 min IV, i.e. 3 Developed by the SNMMI PET Center of Excellence and the Center for Molecular Imaging Innovation & Translation December 2012 - 3 NH3 [13N]ammonia min after the completion of dipyridamole). • Start imaging 3 minutes after the injection of 13N-ammonia and acquire images for a total of 10-20 minutes. Reference: Feinstein Institute for Medical Research, Highlights of Prescribing Information for Ammonia 13N Injection for intravenous use. Recent work indicates that dynamic imaging provides added useful clinical data because the time activity curves can be analyzed to quantify myocardial blood flow, and provide information on myocardial flow reserve in addition to the semi-quantitative results of static perfusion image analysis. (Alesssio 2012, Beller 2012, Fiechter 2012, Herzog 2009, Murthy 2012a /b, Saraste 2012). Human Imaging Experience • IND is an investigational new drug application, NDA is new drug application, ANDA is an amended new drug application. Listed below are selected references for 13N-ammonia injection. Because this is a drug that is administered primarily as a clinical drug under NDA with the FDA, the principle reference that is provided is the prescribing information available on the FDA website. Adeva MM et al. Ammonium Metabolism in Humans. Metabolism 2012; 61:1495-1511. Alessio AM et al. Validation of an axially distributed model for quantification of myocardial blood flow using 13N-ammonia PET. J Nucl Cardiol 2013; 20:64-75. Beller G. Quantification of myocardial blood flow with PET: Ready for clinical application. Editorial. J Nucl Cardiol 2012; 19:877-878. Berridge MS et al. In-target Production of [13N]Ammonia: Target Design, Products and Operating Parameters. Appl Radiat Isot 1993; 44 (12) 1433-1441. Cheng, KT. [13N]Ammonia. Molecular Imaging and Contrast Agent Database (MICAD), Bethesda (MD): National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/pubmed/books/NBK23075/ pdf/AmmoniaN13.pdf Feinstein Institute for Medical Research (Chaly T). Highlights of Prescribing Information for Ammonia N 13 Injection for intravenous Use. 2011, Initial approval 2007 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022119Orig1s001.pdf Developed by the SNMMI PET Center of Excellence and the Center for Molecular Imaging Innovation & Translation December 2012 - 4 NH3 [13N]ammonia Fiecter M. Diagnostic Value of 13N-Ammonia Myocardial Perfusion PET: Added Value of Myocardial Flow Reserve. J Nucl Med 2012; 53:1230-1234. Herzog, BA et al. Long-Term Prognostic Value of 13N-Ammonia for Myocardial Perfusion Positron Emission Tomography. JACC 2009; 54:150-156. International Commission on Radiological Protection (ICRP) Task Group Committees 2 and 3. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 53 and Addendum 1. Pages 61-62. Pergamon Press. New York, NY. 1994. (Also referenced as ICRP Vol 18 (1-4)) Khademi S et al. Mechanism of Ammonia Transport by Amt/MEP/Rh: Structure of AmtB at 1.35 Å. Science 2004; 305:1587-1594. Murthy VL et al. Association between Coronary Vascular Dysfunction and Cardiac Mortality in Patients with and without Diabetes Mellitus. Circulation 2012a; 121:1801-1811. Murthy VL et al. Non-invasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease. J Nucl Cardiol 2012; 19:1060-1072. Saraste A. PET: Is myocardial flow quantification a clinical reality? J Nucl Cardiol 2012; 19:1044-1059. SNMMI would like to acknowledge Jeanne Link, PhD for her contributions to developing this content. Developed by the SNMMI PET Center of Excellence and the Center for Molecular Imaging Innovation & Translation December 2012 - 5